Broadcast Date: Tuesday, January 14, 2020
from 3:00 pm to 4:30 pm (ET)


In recent years, the hope on solving the patent eligibility conundrum is still up in the air. Precedential decisions interpreting and applying Section 101 from both the Supreme Court and the Federal Circuit created tangled patent eligibility rulings that have limited the ability to patent certain technologies. In connection with this, earlier this year, the members of the Senate Judiciary Subcommittee on Intellectual Property, along with members of the House, have produced a draft bill that will revise 35 U.S.C. Section 101. However, this draft bill is not yet available for there are still a lot of details to be discussed, and the proposed legislation is still to be determined.  A mutual effort to produce a consistent subject matter eligibility framework is both an achievement and a raising opportunity for the year ahead.

In this LIVE Webcast, a seasoned panel of thought leaders and professionals brought together by The Knowledge Group will provide and present to the audience an in-depth analysis of the fundamentals as well as recent developments in Overcoming Sections 101,102, 103 Conundrum for Biotech and Chemical Patents. Speakers will also present all the important issues surrounding this significant topic including its impact on Biotech and Chemical Patents.

Key topics include:

  • Guiding Principles for Patent Eligibility
  • Updated Framework for Patent Eligibility
  • Section 101, 102, & 103 Conundrums
  • Impacts on Biotech and Chemical Patent
  • What Lies Ahead


Course Level:



Advance Preparation:

Print and review course materials


Method of Presentation:

On-demand Webcast (CLE)



General knowledge of patent laws


Course Code:



NY Category of CLE Credit:

Areas of Professional Practice


Total Credits:

1.5 CLE

Speaker Panel:

Brendan Gavin, Attorney
White & Case

Brendan is an associate in the Intellectual Property Group at White & Case and has more than 10 years of experience working in the field of patent law.  His practice focuses on a variety of intellectual property issues, including worldwide patent portfolio development, patent prosecution, due diligence, and litigation support.  Brendan has extensive experience providing freedom-to-operate, invalidity and patentability opinions, and he also assists the patent litigation group in contested proceedings, such as inter partes review and post grant review proceedings.  Brendan regularly works with clients and inventors from large corporations, start-up companies and universities to develop ideal intellectual property protection strategies of technologies such as enzyme replacement therapies, modified polypeptides, fusion proteins, small molecules, nucleic acid therapeutics (including CRISPR and RNAi), antibody development, methods of treatment, diagnostic methods, drug formulations, and dosage regimens.

Leslie Kushner, Litigation Counsel
Pearl Cohen Zedek Latzer Baratz LLP

Leslie Kushner is Counsel in the Litigation Group at Pearl Cohen’s New York office. She is an experienced intellectual property attorney, with extensive background in life sciences, biotechnology, and biochemistry. Dr. Kushner utilizes her decades of experience as a biomedical research scientist to represent clients in complex patent (including Hatch-Waxman), trade secret, and contract litigation across various industries, focusing her practice on chemical, biotechnological, pharmaceutical, diagnostic and medical device matters. She also counsels clients on patent validity and freedom-to-operate, performs intellectual property due diligence investigations, and negotiates and drafts licensing, joint venture, and consulting agreements.

Dr. Kushner’s experience includes patent infringement litigation pertaining to pharmaceutical and biotechnological inventions, trade secret litigation pertaining to drug formulations and educational services, copyright litigation pertaining to the entertainment industry, and contract litigation pertaining to biotechnological methods and educational services. Dr. Kushner has provided professional opinions on small-molecule pharmaceuticals, antibodies, cytokines, oligonucleotides, siRNA, enzyme inhibitors, and automotive parts, and has performed due diligence analyses for firms in the pharmaceutical, biotechnological, food, and gaming industries.


Brendan GavinAttorney

White & Case


Leslie KushnerLitigation Counsel

Pearl Cohen Zedek Latzer Baratz LLP


  • Guiding Principles for Patent Eligibility
  • Updated Framework for Patent Eligibility
  • Section 101, 102, & 103 Conundrums
  • Impacts on Biotech and Chemical Patent
  • What Lies Ahead

Date & Time:

Tuesday, January 14, 2020

3:00 pm to 4:30 pm (ET)

Who Should Attend:

  • Patent Lawyers and Consultants
  • Patent Agents
  • Intellectual Property Lawyers
  • Patent Examiners
  • Corporate Counsel
Preventing Ransomware Attacks: A Practical Guide to Enhancing IT Security and Resiliency,
Speaker Preferred Package (Online Payment)
Asbestos Litigation: Demystifying Trends, Developments, and Defense Strategies,
New York Online CLE Bundle
Pennsylvania Online CLE Bundle
California Online CLE Bundle
Supercharging Privilege Review With AI, Analytics, and Automation,
The Hows and Whys of Child Abuse Reporting: A Comprehensive Ethical Guide for Lawyers,
Understanding R&D Tax Credits and Amortization: Navigating Changes and Maximizing Benefits,
Maximizing Your Innovation ROI: R&D Tax Credits in 2024 and Beyond,
Winning Patent Litigation: Essential Strategies and Tactics,
Cartel Investigations: A Blueprint for Defense,
Demystifying Economic Sanctions: Strategies for Success in a Global Economy,
Antitrust 'No-Poach' Agreement Enforcement: Key Focus Areas in 2024,
Practical Trademark Perspectives from U.S. and Canadian Counsel,
Effectively Manage KYC Compliance: Keep Up with the Times by Getting Back to Basics,
OFAC Regulations and the Economic Sanctions Compliance Programs: Best Practices,
'Zombie' LIBOR for USD Contracts: Navigating the Critical Issues, ,
Calculating Lost Profits in Construction Claims: A Practical Guide,
False Claims Act and COVID-19 Implications: Key Considerations and Best Practices, ,


Brendan GavinAttorney
White & Case
Leslie KushnerLitigation Counsel
Pearl Cohen Zedek Latzer Baratz LLP



View Details


View Details


View Details

Join Over 160,000 Professionals Empowering Their Careers

Learn anywhere from over 3000+ live and recorded CLE, CPE & Technology Webcasts.